PDGFRB and telomere syndrome: However, given the potential involvement of the PDGFR pathway in the development of STS and various pediatric malignancies where the PDGFR pathway is implicated,5 and the lack of any new first‐line treatments in the last 40 years, the PDGFR pathway remains a potential target for new therapeutics.